Article citationsMore>>

Pujade-Lauraine, E., Ledermann, J.A., Selle, F., Gebski, V., Penson, R.T., Oza, A.M., et al. (2017) Olaparib Tablets as Maintenance Therapy in Patients with Platinum-Sensitive, Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 18, 1274-1284.
https://doi.org/10.1016/S1470-2045(17)30469-2

has been cited by the following article:

• TITLE: Treatment Free Intervals after Subsequent Chemotherapy Lines in Recurrent Ovarian Cancer

  AUTHORS: Hanna Sallinen, Vivi Rintanen, Leea Keski-Nisula, Maarit Anttila

  KEYWORDS: Ovarian Cancer, Chemotherapy, Treatment Free Interval, Overall Survival, Progression Free Survival, Aggressive Care

  JOURNAL NAME: Journal of Cancer Therapy, Vol.12 No.6, June 9, 2021

  ABSTRACT: Aim: Despite recent advances in the treatment of ovarian cancer, recurrence of the disease is still frequent. This study evaluated whether multiple lines of chemotherapy have impact on overall survival (OS), progression free survival (PFS) or on treatment free intervals (TFIs) after serial chemotherapy lines in recurrent settings. Methods: A total of 189 patients with ovarian cancer (including fallopian tube and primary peritoneal cancer), who were treated in Kuopio University Hospital in Finland during 2009-2014, were enrolled. The medical files of these patients were retrospectively reviewed. Results: Median OS and PFS were significantly higher at the time of the first relapse compared to subsequent relapses (p platinum sensitive, semi-sensitive and platinum resistant patients. The total amount of TFI times during the whole follow-up time was significantly reduced in those patients that received at least one form of aggressive care at the end of life (p = 0.004). Conclusions: Ovarian cancer patients received often multiple lines of chemotherapy. TFIs after subsequent chemotherapy lines decreased during the disease course. More efforts should be taken to avoid unnecessary and ineffective treatments especially in recurrent phase of the disease.